G1 Therapeutics Inc (NASDAQ:GTHX) – Analysts at B. Riley issued their FY2018 EPS estimates for G1 Therapeutics in a note issued to investors on Thursday, February 7th. B. Riley analyst H. Polishetty anticipates that the company will post earnings of ($2.57) per share for the year. B. Riley currently has a “Buy” rating and a $55.00 target price on the stock. B. Riley also issued estimates for G1 Therapeutics’ Q4 2018 earnings at ($0.66) EPS, FY2019 earnings at ($3.10) EPS, FY2020 earnings at ($3.60) EPS, FY2021 earnings at ($3.23) EPS, FY2022 earnings at ($1.87) EPS and FY2023 earnings at $1.90 EPS.
A number of other equities analysts have also commented on the stock. JPMorgan Chase & Co. lowered shares of G1 Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $59.00 to $41.00 in a research report on Wednesday, January 23rd. Raymond James initiated coverage on shares of G1 Therapeutics in a research report on Wednesday, December 19th. They set a “strong-buy” rating on the stock. BidaskClub lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 25th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research report on Sunday, November 11th. Finally, Needham & Company LLC reduced their target price on shares of G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research report on Thursday, November 8th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $66.00.
A number of hedge funds have recently modified their holdings of GTHX. FMR LLC increased its holdings in G1 Therapeutics by 1.2% during the second quarter. FMR LLC now owns 4,902,732 shares of the company’s stock valued at $213,073,000 after buying an additional 57,156 shares during the period. Bank of America Corp DE increased its holdings in G1 Therapeutics by 4.6% during the second quarter. Bank of America Corp DE now owns 267,471 shares of the company’s stock valued at $11,624,000 after buying an additional 11,877 shares during the period. California Public Employees Retirement System purchased a new position in G1 Therapeutics during the second quarter valued at approximately $1,643,000. Bank of New York Mellon Corp increased its holdings in G1 Therapeutics by 1,497.7% during the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after buying an additional 1,183,940 shares during the period. Finally, Northern Trust Corp increased its holdings in G1 Therapeutics by 55.0% during the second quarter. Northern Trust Corp now owns 242,495 shares of the company’s stock valued at $10,538,000 after buying an additional 86,058 shares during the period. 70.06% of the stock is currently owned by institutional investors.
In related news, CFO Barclay A. Phillips sold 5,000 shares of G1 Therapeutics stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $39.92, for a total transaction of $199,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $39.75, for a total transaction of $150,096.00. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 3,420 shares of company stock worth $77,599 and have sold 26,825 shares worth $1,017,352. Company insiders own 15.92% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Read More: Backdoor Roth IRA
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.